Vanguard Group’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $665M | Buy |
6,210,916
+1,214,489
| +24% | +$129M | 0.01% | 887 |
|
|
2025
Q3 | $505M | Buy |
4,996,427
+1,407,313
| +39% | +$131M | 0.01% | 1063 |
|
|
2025
Q2 | $227M | Buy |
3,589,114
+144,188
| +4% | +$8.83M | ﹤0.01% | 1456 |
|
|
2025
Q1 | $182M | Buy |
3,444,926
+2,326
| +0.1% | +$129K | ﹤0.01% | 1526 |
|
|
2024
Q4 | $193M | Sell |
3,442,600
-5,311
| -0.2% | -$293K | ﹤0.01% | 1561 |
|
|
2024
Q3 | $181M | Buy |
3,447,911
+87,216
| +3% | +$4.18M | ﹤0.01% | 1592 |
|
|
2024
Q2 | $138M | Buy |
3,360,695
+56,549
| +2% | +$2.26M | ﹤0.01% | 1695 |
|
|
2024
Q1 | $143M | Buy |
3,304,146
+77,208
| +2% | +$3.38M | ﹤0.01% | 1685 |
|
|
2023
Q4 | $148M | Buy |
3,226,938
+212,370
| +7% | +$6.7M | ﹤0.01% | 1664 |
|
|
2023
Q3 | $69.1M | Buy |
3,014,568
+85,139
| +3% | +$1.91M | ﹤0.01% | 1982 |
|
|
2023
Q2 | $48.3M | Buy |
2,929,429
+281,293
| +11% | +$5.08M | ﹤0.01% | 2199 |
|
|
2023
Q1 | $47.2M | Buy |
2,648,136
+51,822
| +2% | +$1.3M | ﹤0.01% | 2204 |
|
|
2022
Q4 | $75.6M | Buy |
2,596,314
+362,042
| +16% | +$9.3M | ﹤0.01% | 1954 |
|
|
2022
Q3 | $54.7M | Buy |
2,234,272
+84,546
| +4% | +$1.57M | ﹤0.01% | 2136 |
|
|
2022
Q2 | $8.92M | Sell |
2,149,726
-107,294
| -5% | -$587K | ﹤0.01% | 3059 |
|
|
2022
Q1 | $26M | Sell |
2,257,020
-66,501
| -3% | -$584K | ﹤0.01% | 2634 |
|
|
2021
Q4 | $23.2M | Buy |
2,323,521
+10,443
| +0.5% | +$117K | ﹤0.01% | 2768 |
|
|
2021
Q3 | $30.2M | Buy |
2,313,078
+55,656
| +2% | +$850K | ﹤0.01% | 2640 |
|
|
2021
Q2 | $44.2M | Buy |
2,257,422
+5,027
| +0.2% | +$104K | ﹤0.01% | 2446 |
|
|
2021
Q1 | $47.9M | Buy |
2,252,395
+366,871
| +19% | +$10.6M | ﹤0.01% | 2340 |
|
|
2020
Q4 | $56.1M | Sell |
1,885,524
-5,514
| -0.3% | -$140K | ﹤0.01% | 2137 |
|
|
2020
Q3 | $41M | Sell |
1,891,038
-79,985
| -4% | -$1.83M | ﹤0.01% | 2113 |
|
|
2020
Q2 | $44M | Buy |
1,971,023
+260,210
| +15% | +$5.07M | ﹤0.01% | 2067 |
|
|
2020
Q1 | $26M | Buy |
1,710,813
+31,340
| +2% | +$561K | ﹤0.01% | 2177 |
|
|
2019
Q4 | $38.6M | Buy |
1,679,473
+400,194
| +31% | +$8.89M | ﹤0.01% | 2222 |
|
|
2019
Q3 | $27.6M | Buy |
1,279,279
+92,019
| +8% | +$1.97M | ﹤0.01% | 2318 |
|
|
2019
Q2 | $26.1M | Buy |
1,187,260
+35,270
| +3% | +$891K | ﹤0.01% | 2381 |
|
|
2019
Q1 | $31.6M | Buy |
1,151,990
+69,525
| +6% | +$2M | ﹤0.01% | 2298 |
|
|
2018
Q4 | $29.1M | Buy |
1,082,465
+34,279
| +3% | +$947K | ﹤0.01% | 2276 |
|
|
2018
Q3 | $30.6M | Buy |
1,048,186
+115,177
| +12% | +$3.64M | ﹤0.01% | 2376 |
|
|
2018
Q2 | $29.2M | Buy |
933,009
+530,097
| +132% | +$14.5M | ﹤0.01% | 2396 |
|
|
2018
Q1 | $8.02M | Sell |
402,912
-74,521
| -16% | -$1.98M | ﹤0.01% | 2936 |
|
|
2017
Q4 | $13.9M | Buy |
+477,433
| New | +$12.6M | ﹤0.01% | 2671 |
|
Other funds holding RYTM
RCM
BBA
NMC
PA
Vanguard Group's RYTM Position: Q4 2025 in Review
Vanguard Group increased its Rhythm Pharmaceuticals (RYTM) stake by 24% in Q4 2025, buying an estimated $129M and bringing the position to 6,210,916 shares worth $665M. The position accounts for 0.01% of the portfolio, ranked #887.
Vanguard Group first reported a position in RYTM in Q4 2017 and has held it in 33 quarters since. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.
- Vanguard Group held 6,210,916 shares of Rhythm Pharmaceuticals worth $665M as of Q4 2025.
- Vanguard Group bought 1,214,489 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $129M.
- Rhythm Pharmaceuticals made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #887 holding.
- Vanguard Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 33 quarters since.
- 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.